Liver Cancer
Copyright ©The Author(s) 2004.
World J Gastroenterol. Mar 1, 2004; 10(5): 649-653
Published online Mar 1, 2004. doi: 10.3748/wjg.v10.i5.649
Table 1 Description of cases
Age (yr)
Median58 ± 14.1
Range21-86
Sex
Male81
Female18
Modality of diagnosis
Cytological/histological33
Imaging + AFP > 400 ng/mL30
Imaging + AFP < 400 ng/mL or unknown36
Cirrhosis
Absent5
Present80
Chronic parenchymalds’14
Causes of liver disease
Hepatitis B58
Hepatitis C22
Hepatitis B + C5
Non B and Non C6
Alcoholic1
Child-Pugh stage (unknown = 2)
A43
B33
C21
AFP (ng/mL) (unknown = 10)
10 <17
11-40033
40039
Portal vein thrombosis (unknown = 3)
No46
Yes50
Pre ThalidomideTreatment (unknown = 7)
No30
Yes72
Surgery11
PEI16
TACE49
Radiation6
Chemotherpay3
Table 2 Okuda staging for HCC
Point01
Size of tumor< 50% of liver> 50 %
AscitesNoYes
Albumin≥ 3< 3
Bilirubin< 3≥ 3
Stage I: 0II: 1 or 2III: 3 or 4
Table 3 CLIP scoring system
Scores Variables012
Child-pugh stageABC
Tumor morphologyUnninodularMultinodularMassive
and extensionand extensionor extension
≤ 50% ≤ 50%> 50%
AFP< 400≥ 400
Portal vein thrombosisNoYes
Table 4 Hepatocellular carcinoma stage and survival time, Okuda stage and survival time
GroupStage
MSD
IIIIII
A (n = 19)Case No.595
Survival days16126.810.525.2
B (n = 76)Case No.194116
Survival days171.5136.547.3108.5
Table 5 Hepatocellular carcinoma stage and survival time, CLIP classification and survival time
GroupScore
0123456
A (n = 20)Case0222851
Survival days220.549423512.311
B (n = 76)Case1820201593
Survival days> 345301150.5106.896.259.519.3
Table 6 Response rate of hepatoma treated with thalidomide
Tumor response
Stabilization rate
NCR/PRSDPD(PR + SD)
Patt et al[6]210/111912 (57%)
Chen et al[8]420/2152517 (43%)
Kong et al[5]110/1465 (45%)
Lin et al[4]270/11252 (8%)
Schwartz et al[7]201/17119 (45%)
Total1211/6387645 (37%)
Wang et al990/6Survival 16 upto Apr 31 ’03